Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Taxes (2016 - 2020)

Historic Change in Taxes for Harvard Bioscience (HBIO) over the last 12 years, with Q3 2020 value amounting to -$241000.0.

  • Harvard Bioscience's Change in Taxes fell 478.26% to -$241000.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $330000.0, marking a year-over-year increase of 27368.42%. This contributed to the annual value of -$363000.0 for FY2019, which is 15931.37% down from last year.
  • Latest data reveals that Harvard Bioscience reported Change in Taxes of -$241000.0 as of Q3 2020, which was down 478.26% from $337000.0 recorded in Q2 2020.
  • In the past 5 years, Harvard Bioscience's Change in Taxes registered a high of $555000.0 during Q3 2018, and its lowest value of -$741000.0 during Q2 2019.
  • Over the past 5 years, Harvard Bioscience's median Change in Taxes value was $6000.0 (recorded in 2020), while the average stood at $19368.4.
  • In the last 5 years, Harvard Bioscience's Change in Taxes soared by 57837.84% in 2017 and then plummeted by 105740.74% in 2018.
  • Harvard Bioscience's Change in Taxes (Quarter) stood at -$37000.0 in 2016, then soared by 578.38% to $177000.0 in 2017, then surged by 126.55% to $401000.0 in 2018, then plummeted by 43.14% to $228000.0 in 2019, then crashed by 205.7% to -$241000.0 in 2020.
  • Its Change in Taxes was -$241000.0 in Q3 2020, compared to $337000.0 in Q2 2020 and $6000.0 in Q1 2020.